期刊文献+

碳青霉烯类抗菌药物对大肠埃希菌、肺炎克雷伯菌、铜绿假单胞菌、鲍曼不动杆菌的防突变浓度研究 被引量:31

Mutant preventing concentrations of carbapenem antibiotics against Escherichia coli,Klebsiella pneumoniae,Pseudomonas aeruginosa,Acinetobacter Bauman
原文传递
导出
摘要 目的:探索碳青霉烯类抗菌药物对临床分离的100株大肠埃希菌、肺炎克雷伯菌β-内酰胺酶表型和铜绿假单胞菌、鲍曼不动杆菌的防突变浓度(MPC)。方法:采用琼脂稀释法测定碳青霉烯类(亚胺培南、美洛培南、厄他培南和多利培南)对临床分离的革兰阴性耐药菌株的最低抑菌浓度(MIC)及MPC并计算MPC/MIC比值。采用WHONET5.6及SPASS13.0进行分析。结果:肠杆菌科细菌和鲍曼不动杆菌的MPC/MIC比值为2~4,铜绿假单胞菌为4-≥16。β-内酰胺酶阳性的肺炎克雷伯菌、大肠埃希菌MPC/MIC比值高于β-内酰胺酶阴性菌株(4至〉16μg·mL-1)。结论:基于MPC的碳青霉烯类抗菌药物可以通过MPC/MIC比值调整给药剂量,降低耐药菌株的总体数量和感染负荷,抑制耐药菌突变体的选择性富集扩增。 OBJECTIVE To explore mutant preventing concentrations (MPC) of carbapenem antibiotics against clinical iso- lates of 100 strains of Escherichia coli, Klebsiella pneumoniae ESBLs phenotype, Pseudomonas aeruginosa and Acinetohacter Bauman. METItODS Minimal inhibitory concentration (MIC) and MPC of carhapenems (imipenem, meropenem and ertapen- em, doripenem) were determined using agar dilution method for gram negative strains of clinical isolates to calculate the ratio of MPC/MIC. WHONET 5.6 and SPASS 13.0 were used for analysis. RESULTS Real ratios of MPC/MIC were 2 - 4 for Enter- ohacteriaceae coli and Acinetohacter Bauman, and 4 - ≥ 16 for Pseudomonas aeruginosa. Beta lactamase positive Klebsiella pneumoniae and Escheriehia coli had higher MPC/MIC ratios than those for beta lactamase negative strains (4 to 〉16 g·mL-1 ). CONCLUSION Carhapenem antibiotics based on MPC can adjust dose according to MPC/MIC ratios, reduce total quantity and burden of infection resistant strains, inhibit selective enrichment and amplification of mutant resistant bacteria.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2016年第2期130-135,共6页 Chinese Journal of Hospital Pharmacy
基金 云南省科技厅-昆明医科大学应用基础研究联合专项基金(编号:2013FB145)
关键词 碳青霉烯类 防突变浓度 最低抑菌浓度 防突变浓度/最低抑菌浓度 β-内酰胺酶表型 大肠埃希菌、肺炎克雷伯菌、铜绿假单胞菌、鲍曼不动杆菌 carbapenems MPC MIC MPC/MIC beta lactamase phenotype Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa Acinetobacter P, auman
  • 相关文献

参考文献33

  • 1Blondeau JM, Borsos SD, Sanche SE. Comparative minimum inhibitory concentration (MIC) or mutant prevention concentration(MPC) values for tigecycline (Tig) and vancomycin (Van) tested against toxin positive Clostridium difficile (CD) clinical isolates, poster E-208. Abstr.49th Intersci. Conf[J].Antimicrob Agents Chemother,2009,53(9):543-548.
  • 2Drawz SM,Papp-Wallace KM,Bonomo RA.New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world[J]. Antimicrob Agents Chemother, 2014,58(4) 1835-1846.
  • 3Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa:a systematic review of the literature[J]. J Hosp Infect, 2006, 64(1):7-15.
  • 4Prevalence of multi drug resistant Acinetobacter baumannii in the clinical samples from Tertiary Care Hospital in Islamabad[J]. Pakistan Pak J Med Sci, 2013,29(5): 1253-1258.
  • 5李朝霞,刘又宁.细菌耐药突变选择窗理论与抗菌药物合理应用[J].中国药学杂志,2006,41(16):1201-1205. 被引量:31
  • 6Mutant prevention concentration of tigecycline for clinical isolates of Streptococcus pneumoniae and Staphyl-ococcus aureus[J].Antimicrob Chemother,2015,70(2): 494-497.
  • 7Hesje CK, Tillotson GS,Blondeau JM. MICs, MPCs and PK/PDs: a match (sometimes) made in hosts. Expert Rev[J].Respir Med,2007,1(1):7-16.
  • 8Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves[J]. Res Vet Sci, 2013,935(3): 1114-1124.
  • 9Smith HJ, Nichol KA, Hoban DJ,et al. Stretching the mutant prevention concentration (MPC) beyond its limits[J].J Antimicrob Chemother,2003,51(6):1323 1325.
  • 10Zhao X, Eisner W, Perl-Rosenthal N, et al. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or resistant Staphylococcus aureus[J]. Antimicrob Agents Chemother,2003,47(3):1023-1027.

二级参考文献64

  • 1赵彩芸,李家泰,张莉,张朴,刘燕.单次静脉美罗培南在健康人体的药代动力学[J].中国临床药理学杂志,2004,20(3):189-192. 被引量:25
  • 2ZHAO X,Restricting the selection of antibiotic-resistant mutant:a general strategy drived from fluoroquinolones studies[J].Clin Infect Dis,2001 ;33:S147-156.
  • 3DRLICA K.A strategy for fighting antibiotic resistance[J].ASM News,2001,67:27-33.
  • 4BAQUERO F.Resistance to quinolones in gram-negative microorganisms:-mechanisms and prevention[J].Eur Urol,1990,17(suppl 1):3-12.
  • 5DONG Y,ZHAO X,DOMAGALA J,et al.Effect of fluoroquinolone concentration on selection of resistant mutants of mycobacterium bovis BCG and staphylococcus aureus[J].Antimicrob Agents Chemother,1999,43:1756-1758.
  • 6ZHAO X,DRLICA K.Restricting the selection of antibiotic-resistant mutant bacteria:-measurement and potential use of the mutant selection window[J].Infect Dis,2002,185(4):561-565.
  • 7SMITH H J,NICHOL K A,HOBAN D J,et al.Stretching the mutant prevention concentration (MPC) beyond its limits[J].Antimicrob Chemother,2003,51 (6):1323-1325.
  • 8ZHAO X.Clarification of MPC and the mutant selection window concept[J].Antimicrob Chemother,2003,52:731.
  • 9LU T,ZHAO X,LI X,et al.Effect of chloramphenicol,erythromycin,moxifloxacin,penicillin and tetracycline concentration on the recovery of resistant mutants of mycobacterium smegmatis and staphylococcus aureus[J].Antimicrob Chemother,2003,52(1):61-64.
  • 10RODRIGUEZ J C,CEBRIAN L,LOPEZ M,et al.Mutant prevention concentration:comparison of fluoroquinolones and linezolid with mycobacterium tuberculosis[J].Antimicrob Chemother,2004,53(3):441-444.

共引文献42

同被引文献336

引证文献31

二级引证文献156

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部